A Phase I Study to Characterize the Tolerance, Safety, Pharmacokinetics/Pharmacodynamics and Effect of PD-1 Inhibitor SHR-1210 in Combination With IDO Inhibitor SHR9146 and With/Without Apatinib in Patients With Advanced Solid Tumors (PIANO)

Trial Profile

A Phase I Study to Characterize the Tolerance, Safety, Pharmacokinetics/Pharmacodynamics and Effect of PD-1 Inhibitor SHR-1210 in Combination With IDO Inhibitor SHR9146 and With/Without Apatinib in Patients With Advanced Solid Tumors (PIANO)

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2018

At a glance

  • Drugs Camrelizumab (Primary) ; HTI 1090 (Primary) ; Rivoceranib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms PIANO
  • Sponsors Jiangsu Hengrui Medicine Co.
  • Most Recent Events

    • 02 Jun 2018 Planned initiation date changed from 1 May 2018 to 1 Jul 2018.
    • 13 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top